Diagnostic Performance and Safety Profile of Shape-Sensing Robotic-Assisted Bronchoscopy in Peripheral Pulmonary Lesions: A Systematic Review and Meta-Analysis
Respiration · 2026-10-10 · 1-1
DOI: 10.1159/res/aepag020 ↗Abstract
Introduction: Shape-sensing robotic-assisted bronchoscopy (ssRAB) has emerged as a promising modality for diagnosing peripheral pulmonary lesions. This meta-analysis evaluated its diagnostic performance and safety profile. Methods: PubMed, Embase, and Cochrane Library were searched from inception to December 2025. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-3. Random-effects model was used to estimate the pooled diagnostic yield, sensitivity for malignancy, and complication, with rates (%) and 95% confidence intervals (CI) when the I2 index exceeded 50%. Cumulative meta-analysis was performed to assess the temporal stability and evidence saturation of the pooled diagnostic yield. Publication bias was evaluated using funnel plots and Egger’s test. Results: A total of 3,678 lesions from 18 studies were included. Notably, diagnostic yield varied significantly by outcome definition, with pooled diagnostic yield of 82.5% (95% CI: 78.3%–86.0%) under strict definition vs. 88.1% (95% CI: 82.8%–92.0%) under the intermediate definition (p = 0.036). The pooled sensitivity for malignancy of 90.0% (95% CI: 86.4%–92.8%). Cumulative meta-analysis showed stabilized diagnostic performance after approximately 1,500 lesions for the strict definition and 500 lesions for intermediate definition. Moreover, the safety profile was favorable, with pooled rates of pneumothorax of 1.8% (95% CI: 1.3%–2.3%), chest tube placement of 1.1% (95% CI: 0.7%–1.5%), and severe bleeding of 0.0% (95% CI: 0.0%–0.3%). Subgroup analyses showed consistent performance across study designs, region, and nodule characteristics. Diagnostic yield was significantly influenced by publication year and lesion size (p < 0.05). Conclusion: ssRAB was associated with favorable, definition-dependent diagnostic yield (82.5%–88.1%) with exceptional safety, supporting ssRAB as an attractive first-line minimally invasive diagnostic option in appropriately selected patients, especially for small nodules (
EUVIMED